Study Findings from Second Affiliated Hospital of Zhejiang Chinese Medical University Update Knowledge in Lung Cancer (The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced...).

A study conducted at the Second Affiliated Hospital of Zhejiang Chinese Medical University in China explored the effectiveness and safety of combining anlotinib with third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of advanced non-small cell lung cancer (NSCLC). The study included 121 eligible patients and compared the progression-free survival (PFS) and overall survival (OS) between the combination group and the EGFR-TKI monotherapy group. The results showed that the combination therapy was more effective in terms of PFS compared to EGFR-TKI monotherapy. However, there were no significant differences in OS between the two groups. The study also found that the common adverse reactions in the combination group were diarrhea, hypertension, and proteinuria, but these were clinically manageable. Overall, the study suggests that combining anlotinib with EGFR-TKIs may be a beneficial treatment option for EGFR-mutant NSCLC patients with gradual progression. [Extracted from the article]